INTRODUCTION
============

Carotenoids, poorly soluble lipophilic compounds, are a group of widely distributed plant pigments that have various physiological activities in human and animals. Lutein is one among several carotenoids that has been gaining attention lately because of its ability to prevent ocular diseases including age-related macular degeneration (AMD) and cataracts caused by complications of metabolic disorders such as diabetes [@B015]; [@B030]; [@B003]; [@B006]; [@B021]; [@B025]; [@B008]. Lutein possesses an-tioxidant activity due to its conjugated double bonds that are highly effective in quenching reactive oxygen species that is involved in the pathogenesis of ocular diseases such as AMD and cataracts. Although lutein is a vital macular pigment with many beneficial activities, human is not capable of synthesizing lutein de novo and thus its presence in human tissues is entirely of dietary origin [@B012]; [@B020]; [@B028]; [@B016]. Furthermore, bioavailability of lutein is reported to be very low [@B007]; [@B013]. There have been many studies reported to improve its bioavailability by using various strategies such as mixed micelle and suspension formulations [@B004]; [@B024]; [@B027]; [@B031].

Lipid-based oral drug delivery system has been gaining attention recently with increasing application of lipid as a carrier for the delivery of poorly soluble lipophilic drugs [@B029]; [@B005]. The unique properties of lipids, namely, their physicochemical diversity, biocompatibility, and ability to enhance oral bioavailability of poorly water soluble lipophilic drugs through selective lymphatic uptake have made them attractive candidates as carriers for oral formulations. Among those, self-nanoemulsifying drug delivery system (SNEDDS) is considered as a promising approach to improve solubility and absorption of poorly water soluble lipophilic drugs [@B032]; [@B037]; [@B022]; [@B035].

Although the exact mechanism is not yet fully understood, lutein has been thought to be absorbed through enterocytes by simple diffusion or receptor-mediated transport [@B039]. Primarily, lutein is emulsified into small lipid droplets in the stomach and further incorporated into mixed micelles by the action of bile salts and biliary phospholipids, after which mixed micelles are taken up by enterocytes with the aid of the scavenger receptor class B type I (SR-BI), a member of the ATP-binding cassette (ABC) transporter super-family. Accordingly, it is conceivable that the SNEDDS may enhance gastrointestinal absorption of lutein.

However, the SNEDDS may also affect the gastrointestinal absorption of other drugs. This is especially of concern to drugs with narrow therapeutic index or drugs used for the treatment of chronic diseases. Warfarin is a typical example of such drugs because it is often prescribed for a lifetime and prone to over- or under-coagulation due to pharmacokinetic and pharmacodynamic interaction with other drugs or supplements administered together. There have been many studies about drug interaction of warfarin with other drugs and supplements [@B011]; [@B023]; [@B041]. However, the effect of lutein on the absorption of warfarin has not been reported.

We hypothesized that, although lutein may not cause drug interaction with warfain, large amount of surfactant and co-surfactant used to prepare SNEDDS formulation may affect gastrointestinal absorption of the drug. In this paper, we prepared SNEDDS of lutein to improve dissolution and investigated its effect on the bioavailability of warfarin using rats. Lutein as non-SNEDDS (lutein powder) was also tested to see the effect on the bioavailability of the drug.

MATERIALS AND METHODS
=====================

Materials
---------

Lauroglycol FCC, Labrafil M1944, Labrafil 2125, Labrafac CC, Labrasol, Peceol, and Transcutol-HP were obtained from Gattefosse (Saint-Priest Cedex, France). Lutrol-E400 was obtained from BASF (Florham Park, NJ, USA). Saponified marigold extract and a commercial product (Eyelac^®^) were kindly donated by Korea Arlico Pharm (Seoul, Korea). Warfarin and naproxen were purchased from Sigma-Aldrich (St. Louis, MO, USA). All other chemicals were analytical grade and were used without further purification.

Extraction and purification of lutein
-------------------------------------

Lutein was extracted and purified from saponified marigold extract according to the previously reported methods [@B017]; [@B036]. The purified lutein was characterized by ^1^H NMR, ^13^C NMR, and HPLC. The ^1^H and ^13^C NMR data were in good agreement with the data from literatures [@B001].

Construction of pseudo-ternary phase diagram and preparation of SNEDDS
----------------------------------------------------------------------

Construction of pseudo-ternary phase diagram and preparation of SNEDDS were performed as previously reported [@B040]. Tendency to form an emulsion was judged as 'good' when the droplets spread easily in distilled water resulting in a fine milky emulsion, and it was judged 'bad' when there was poor or no emulsion formation with immediate coalescence of oil droplets, especially when stirring was stopped. In this study, Peceol and Labrasol were selected as oil phase and surfactant, respectively, and Lutrol-E400 and Transcutol-HP were selected as co-surfactants. Concentration of lutein in the SNEDDS was fixed at 2% w/v.

Characterization of physicochemical properties of SNEDDS
--------------------------------------------------------

Physicochemical properties evaluated in this study included zeta potential, droplet size, emulsification time, and dissolution of lutein from the SNEDDS. Procedures for the measurement of the properties followed previously reported method [@B040].

Animal study
------------

All animal treatment was carried out in accordance with Korea National Institute of Health. Seven week old male Sprague Dawley rats were supplied by Orient Bio (Seoul, Korea) and housed in groups not exceeding six per cage. The acclimation period was two weeks before the experimental procedure with a dark/light cycle of 12 h/12 h at a temperature of 23 ± 2℃ and 50-80% relative humidity. The animals had free access to food and water.

The animals were fasted for 10 h before the experiment and randomly assigned to three test groups and a control group (n=6 for each). On experiment day, rats in the three test groups received single doses of warfarin (per oral, 1.5 mg/kg) suspended in corn oil (2 ml/kg) and lutein as System A, System B, or non-SNEDDS (per oral, 5 mg/kg). Corn oil was used as suspending agent because it is physiologically inactive and has minimal solubility for both warfarin and lutein. For lutein as non-SNEDDS, lutein powder was administered as suspension in corn oil with warfarin. SNEDDS formulations containing lutein was diluted appropriately with distilled water before administration so that the volume of the formulation was 0.5 ml. Rats in the control group received warfarin only. Blood samples of 0.3 ml were serially withdrawn under anesthesia via the subclavian vein into small heparinized Eppendorf tubes at predetermined time intervals for 5 days. The blood samples were immediately centrifuged at 2,000 rpm for 7 min, and the plasma was removed and stored at -20℃ until HPLC assay of warfarin concentration.

HPLC assay of warfarin in plasma
--------------------------------

The warfarin content of rat plasma samples was assayed by HPLC equipped with Class VP computer software, LC 10 AD VP pump, and SPD 10A UV-VIS detector at 310 nm using naproxen as internal standard. The column was Inertsil ODS-3 (4.6×150 mm, GL Science Inc, Japan) and the mobile phase consisted of a mixture of 0.02 M phosphate buffer and acetonitrile (50:50) adjusted to pH 3.5 with 1 N HCl. Flow rate was 1.0 ml/min and the injection volume of the sample was 20 μl. Before measuring the plasma level of warfarin by HPLC, validation of the assay was performed by repeating five times a day for five consecutive days using exactly the same conditions for warfarin concentration range of 50-15,000 ng/ml.

The frozen plasma samples were thawed at room temperature and 100 μl aliquots were spiked with 30 μl of internal standard (naproxen in methanol). After brief vortex mixing, 150 μl of phosphate buffer (pH 2.0) was added to acidify the plasma for effective extraction. One milliliter of diethyl ether was added for deproteination of the plasma sample followed by centrifugation for 1 min at 13,000 *g* to precipitate the proteins, and the clear supernatant was evaporated in a centrifugal vacuum evaporator. The residue obtained was reconstituted with 200 μl of mobile phase and injected to HPLC.

###### 

Composition, HLB value, and solubility profile of vehicles screened for selection of SNEDDS

  ----------------------------- ------------------------------------------------------ ------- --------------------
  Vehicles                      Composition                                            HLB     Solubility (mg/ml)
                                                                                               
  Surfactants/Co-surfactants:                                                                  
    Labrasol                    Caprylocaproyl macrogolglycerides                      14      56.54 ± 4.24
    Lauroglycol-FCC             Propyleneglycol caprylate                              5       7.09 ± 1.18
    Transcutol-HP               Diethylene glycol monoethyl ether                        4.2   16.27 ± 2.35
    Lutrol-E400                 Polyethylene glycol; polyalkylene glycol; polyol       4       31.53 ± 3.27
    Labrafil-M1944              Oleoyl macrogolglycerides                              4       4.35 ± 1.02
    Labrafil-2125               Linoleoyl macrogolglycerides                           4       3.77 ± 1.22
  Oils:                                                                                        
    Labrafac CC                 Caprylic/capric triglycerides                          1       7.83 ± 0.29
    Peceol                      Glyceryl monooleate                                    3       11.76 ± 1.38
    Corn oil                    Linoleic acid 58%; oleic acid 28%; palmitic acid 11%   \-      1.86 ± 0.25
    Cotton seed oil             Linoleic acid 54%; oleic acid 19%; palmitic acid 22%   \-      2.01 ± 0.33
    Peanut oil                  Linoleic acid 32%; oleic acid 48%; palmitic acid 11%   \-      1.46 ± 0.11
    Castor oil                  Ricinoleic acid 95%; oleic acid 2%; linoleic acid 1%   \-      5.55 ± 0.36
  ----------------------------- ------------------------------------------------------ ------- --------------------

![Pseudo-ternary phase diagrams of SNEDDS. (A) System A. (B) System B. Ternary mixtures inside the solid line exhibited self-emulsification, and the self-emulsification efficiency was good when sum of the surfactant and co-surfactant concentration was more than 80% of SNEDDS formulation.](ooomb4-21-173-g001){#F001}

RESULTS
=======

The solubility of lutein in various surfactants, co-surfactants and oils was presented in [Table 1](#T001){ref-type="table"}. Among surfactants and co-surfactants tested, lutein has the highest solubility in Labrasol with 56.54 ± 4.24 mg/ml followed by Lutrol-E400 (31.53 ± 3.27 mg/ml) and Transcutol-HP (16.27 ± 2.35 mg/ml). The lowest solubility of lutein among surfactants and co-surfactants was observed with Labrafil-2125 (3.77 ± 1.22 mg/ml). Peceol showed highest solubility of lutein (11.76 ± 1.38 mg/ml) among the oils screened, and solubility of lutein in all vegetable oils tested was less than 6 mg/ml. Therefore, Labrasol and Peceol were chosen as surfactant and oil, respectively, and Transcutol-HP and Lutrol-E400 were chosen as co-surfactants for the preparation of two different SNEDDS.

Pseudo-ternary phase diagrams of the systems containing oil phase (Peceol), surfactant (Labrasol) and co-surfactants (Transcutol-HP and Lutrol-E400) were shown in [Fig. 1](#F001){ref-type="fig"}. There was no significant difference in the emulsion formation with two different co-surfactants (Transcutol-HP and Lutrol-E400). Self-emulsification was achieved at greater than 50% surfactant concentration, and the self-emulsification efficiency was good when sum of the surfactant and co-surfactant concentration was more than 80% of SNEDDS formulation. In the pseudo-ternary phase diagrams, the ternary mixtures outside the solid line exhibited coalescence of the emulsion droplets.

In our study, we observed that increasing surfactant concentration up to 60% decreased the mean droplet size of emulsion formed (in the absence of co-surfactant). However, the droplet size increased when the surfactant concentration was above 60% (172.3 ± 18.1 nm at 60%, 323.5 ± 21.3 nm at 70%, 391.6 ± 24.7 nm at 80%). The effect of co-surfactants (Transcutol-HP and Lutrol-E400) concentration on the droplet size distribution in SNEDDS was similar to that of surfactant (Labrasol) in the ranges of 0-35% ([Fig. 2](#F002){ref-type="fig"}). A decrease in droplet size was observed with an increase in the co-surfactant concentrations of Transcutol-HP and Lutrol-E400 from 5 to 25%, after which the droplet size was increased. The lowest size was observed at 25% of co-surfactant concentration for both Transcutol-HP and Lutrol-E400, showing 172.8 ± 14.8 nm and 93.2 ± 4.6 nm, respectively ([Table 2](#T002){ref-type="table"}). Among the two Systems tested, System B with component ratio of 60% Labrasol, 15% Peceol, and 25% Lutrol-E400 showed smallest mean droplet size ([Fig. 2](#F002){ref-type="fig"}).

###### 

Vehicle composition, zeta potential, droplet size, and emulsification time of the two SNEDDS formulations

  --------------------------- -------------- ----------------
  Vehicle                     System A       System B
                                             
  Peceol (%)                  15             15
  Labrasol (%)                60             60
  Transcutol-HP (%)           25             \-
  Lutrol-E400 (%)             \-             25
  Zeta potential (mV)         -3.02          -2.17
  Droplet size (nm)           172.8 ± 14.8   93.2 ± 4.6^\*^
  Emulsification time (sec)   15 ± 3         18 ± 2
  --------------------------- -------------- ----------------

\**p*\<0.01 compared to System A.

![Effect of co-surfactant concentration on droplet size of SNEDDS containing fixed surfactant concentration of 60%. Droplet size was decreased as concentration of Transcutol-HP and Lutrol-E400 increased up to 25%. However, when the concentration of the co-surfactants was beyond 25%, the size was increased. The lowest size was observed when the concentrations of Labrasol and Lutrol-E400 were 60% and 25%, respectively.](ooomb4-21-173-g002){#F002}

Emulsification time for both Systems was within 20 sec, showing relatively faster in the System A compared to System B (15 ± 3 vs 18 ± 2 sec). Dissolution profile of the two SNEDDS formulations was shown in [Fig. 3](#F003){ref-type="fig"}. The dissolution of lutein was more than 90% accomplished within 10 min for the System B. Almost complete dissolution was achieved after 15 min while lutein was not detectable from the lutein powder or intra-capsule content of a commercial product (20 mg as of lutein in soft gelatin capsule) even after 4 h. No precipitation or aggregation was found for more than a week after dissolution study of the two SNEDDS formulations.

[Table 3](#T003){ref-type="table"} summarized the pharmacokinetic parameters of warfarin in rats following a single oral dose of 1.5 mg/kg with lutein as non-SNEDDS (lutein powder) or SNEDDS formulations. Time to reach maximum plasma concentration (T~max~) of warfarin was 6 h when the drug was administered with or without 5 mg/kg of lutein as non-SNEDDS while it was 4 h when administered with lutein as SNEDDS formulations. Maximum plasma concentration (C~max~) of warfarin was significantly increased when the drug was administered with lutein as SNEDDS (*p*\<0.01). Area under the curve (AUC) was also increased, but the increase was significant only for the System B (*p*\<0.05). Elimination half life (t~1/2~) of warfarin was slightly shortened with concomitant administration with the SNEDDS formulations. [Fig. 4](#F004){ref-type="fig"} shows plasma level of warfarin as a function of time.

![Dissolution profile of lutein from SNEDDS. Each value represents the mean of three samples ± standard deviation. Dissolution of lutein from SNEDDS was very quick and accomplished within 10 min. System B exhibited faster and more complete dissolution than System A because of its smaller droplet size compared to System A. Undissolved amount of lutein is attributed to lutein in the emulsion droplets trapped by syringe filter (0.2 μm). In contrast, commercial formulation (Eyelac^®^ soft gelatin capsule) and lutein powder did not dissolve lutein even at the end of the dissolution study.](ooomb4-21-173-g003){#F003}

DISCUSSION
==========

Lutein is a very hydrophobic substance which follows same intestinal absorption path as dietary fat. When lutein is administered orally, the drug is emulsified in gastrointestinal tract and incorporated into mixed micelles in the presence of bile salts and biliary phospholipids [@B002]; [@B019]; [@B039]. Therefore, absorption of lutein is affected by inappropriate bile juice secretion in patients with biliary diseases. For this reason, an alternative delivery system that relies on its own self-emulsification ability rather than the aid of bile juice would offer benefit to the elderly or patients who cannot eat food appropriately and have altered digestive functions. Hence, SNEDDS may be an ideal delivery system to improve solubilization and absorption of lutein because it spontaneously forms nanosized droplets of oil in water emulsion in aqueous environment without the aid of bile juice secretion.

There have been several strategies reported to improve bioavailability of lutein. Most widely used are mixed micelles and emulsion formulations with or without dietary fats [@B026]; [@B024]. Among the emulsion formulations, SNEDDS is considered promising approach because it distributes readily in the gastrointestinal tract, and digestive motility of the stomach and intestine provides sufficient agitation for spontaneous formation of emulsion. Furthermore, it does not require costly equipments in the manufacturing process and the emulsion droplet size is far less than a micron which is advantageous for gastrointestinal absorption.

Choosing the right combination of oil base, surfactant, and co-surfactant is one of the important points in designing SNEDDS formulations. Surfactant and co-surfactant molecules get preferentially absorbed at the liquid interface during the process of emulsion formation, reducing the interfacial energy of the system. This helps spontaneous emulsification without high energy input. Thus, well-designed SNEDDS formulation can ensure efficient self-emulsification as well as high solubilization capacity for the drug in the resultant dispersion.

###### 

Pharmacokinetic parameters of warfarin in rats following a single oral dose of 1.5 mg/kg with lutein as non-SNEDDS or SNEDDS formulations (n=6)

  ---------------- ------------------ --------------------------- ------------------------- -------------------------
                   Warfarin only      With lutein as non-SNEDDS   With lutein as system A   With lutein as system B
                                                                                            
  T~max~ (h)       6.00               6.00                        4.00                      4.00
  C~max~ (µg/ml)   5.62 ± 0.11        5.65 ± 0.15                     6.14 ± 0.36^\*\*^       6.34 ± 0.22^\*\*^
  AUC (µg/ml×h)    305.70 ± 9.42      308.89 ± 10.23              313.57 ± 12.24            324.10 ± 10.96^\*^
  t~1/2~ (h)       22.91 ± 1.26       23.89 ± 1.74                21.12 ± 1.86              22.70 ± 1.67 
  ---------------- ------------------ --------------------------- ------------------------- -------------------------

T~max~: time to reach maximum plasma concentration, C~max~: maximum plasma concentration, AUC: area under the curve, t~1/2~: elimination half life, ^\*^*p*\<0.05 and ^\*\*^*p*\<0.01 compared to warfarin only.

![Plasma level of warfarin in rats following a single oral dose of 1.5 mg/kg with lutein as non-SNEDDS or SNEDDS formulations (n=6). T~max~ of warfarin was reached at 4 h when the drug was administered with lutein as SNEDDS while it was 6 h when administered with lutein as non-SNEDDS. C~max~ and AUC of warfarin was significantly increased when the drug was administered with lutein as SNEDDS (*p*\<0.01). Reason for the enhanced bioavailability appears that SNEDDS formulation affected permeability of warfarin through the mucosal membrane of gastrointestinal tract.](ooomb4-21-173-g004){#F004}

In this study, we used Peceol, a glyceride-rich excipient mainly consisted of glyceryl monooleate, as oil base. Rationale for choosing Peceol was based on previous researcher's finding that lipids consisted of monounsaturated fatty acid trended toward better absorption of lutein and other carotenoids in healthy subjects [@B010]. We used Labrasol as surfactant because it showed highest solubility for lutein (56.54 ± 4.24 mg/ml) among the vehicles screened and its HLB value was 14 ([Table 1](#T001){ref-type="table"}). Generally, surfactants with HLB 12-15 are regarded as being of good efficiency for self-emulsification [@B033]; [@B034]; [@B031]. Also, this vehicle is widely used in the pharmaceutical and food industries due to its excellent safety profile [@B018]; [@B038] Labrasol is composed of fatty acid esters of polyethyleneglycol and medium chain fatty acids of caproic acid (C6:0) and caprylic acid (C8:0) (mixture of mono-, di-, and tri-glycerides). We used two different co-surfactants in System A and System B (Transcutol-HP and Lutrol-E400, respectively). Reason for choosing Transcutol-HP and Lutrol-E400 was that they have similar HLB values (4.2 versus 4.0) but different solubility profile for lutein (16.27 versus 31.53 mg/ml, [Table 1](#T001){ref-type="table"}).

Dissolution profile of lutein from System B was faster and more complete than System A because of significantly smaller mean droplet size of System B. Although both Systems instantaneously formed nanoemulsion after introduction to dissolution medium (distilled water), the mean droplet size of System B was about half size of System A. Difference in the solubility of lutein to co-surfactants used in the two Systems might have also contributed to dissolution profile. Lutrol-E400 used as co-surfactant in System B showed about two-folds higher solubility for lutein compared to Transcutol-HP used in System A. Undissolved amount of lutein in the dissolution study is attributed to lutein in the emulsion droplets trapped by syringe filter (0.2 μm).

In contrast to SNEDDS, commercial formulation (Eyelac^®^ soft gelatin capsule) and lutein powder did not dissolve lutein even at the end of the study. Inability of the commercial formulation to dissolve lutein may be due to oily nature of the vehicles that were used. Usually, such commercial product should be taken right after meal so that lutein can be emulsified by physiological emulsifiers such as bile juice. However, the SNEDDS that we have formulated does not need to be taken after meal as was evidenced by very rapid dissolution due to its self-emulsifying ability. This especially offers benefit to the elderly and patients who cannot eat food appropriately.

Previously, we reported that gastrointestinal absorption of lutein was significantly enhanced when administered to rabbits as SNEDDS formulation [@B031]. C~max~ and AUC were enhanced as much as 21-fold and 12-fold compared to lutein powder, respectively. Compared to a commercial product (Eyelac^®^), relative bioavailability of the SNEDDS formulation was also significantly improved, showing about 3-folds increase based on AUC. Although this result was encouraging, there remains a concern that the SNEDDS formulation may affect gastrointestinal absorption of other drugs administered together. Especially if therapeutic index of the concomitantly administered drug is narrow, undesirable drug interactions could occur.

We hypothesized that surfactant and co-surfactant may affect absorption of concomitantly administered drugs because they are usually more than 80% of the SNEDDS formulation in weight basis. In this study, we investigated the effect of SNEDDS formulation of lutein on the pharmacokinetic parameters of warfarin using rats. Although there are many research conducted regarding the drug interaction issue of warfarin, interaction between warfarin and surfactants used in the SNEDDS has not been published so far [@B011]; [@B023]; [@B041]. Since warfarin requires close therapeutic monitoring, bioavailability of the drug is of great concern. In the dispensing practice of warfarin prescription, even generic substitution is discouraged due to the bioavailability difference between commercially available brands [@B009]; [@B014]. Our result showed that C~max~ and AUC of warfarin were increased about 10% when administered concomitantly with SNEDDS containing lutein. T~max~ was also prolonged from 6 h to 4 h. These results clearly identified that SNEDDS formulation affected the absorption of warfarin, leading to bioavailability difference. Exact mechanism for this difference is not yet elucidated, but it appears that SNEDDS formulation affected permeability of warfarin through the mucosal membrane of gastrointestinal tract. This speculation is backed up by the lack of bioavailability change in rats administered with warfarin and lutein as non-SNEDDS. Limitation of this study may be that total amount of blood taken for bioavailability measurement was slightly more than 10% of total blood of the rats tested.

Finally, we hypothesized that surfactants in the SNEDDS formulation of lutein may affect bioavailability of warfarin and identified that the surfactants increased C~max~ and AUC of warfarin. Based on this finding, it is suggested that SNEDDS formulations be administered before or after appropriate time interval when used together with narrow therapeutic range drugs.

Lutein was successfully formulated as SNEDDS for immediate self-emulsification and dissolution by using combination of oil base, surfactant, and co-surfactant. However, surfactants used in the SNEDDS affected bioavailability of warfarin, showing about 10% increase in C~max~ and AUC of the drug in rats. T~max~ was also changed from 6 h to 4 h. Although there is no strict consensus about how much bioavailability change is tolerable, concomitant administration of SNEDDS formulation and drugs with narrow therapeutic range appears to require attention for drug interaction.
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